ABIOMED — Q4 2021 Earnings Presentation
12 slides from ABIOMED's earnings presentation, Apr 29, 2021
Slide 1: Q4 FY 2021 Earnings Call: Financial Results & Operational Highlights
® Recovering Hearts. Saving Lives. Q4 FY 2021 Earnings Call Financial Results & Operational Highlights Recovering Hearts. Saving Lives.
Slide 2: Financial Results, Q4 FY 2021
2 FINANCIAL RESULTS, Q4 FY 2021 Revenue ($M) & Growth Rates Cash* ($M) $848 $241 $788 $232 $736 $210 $651 $207 $597 $165 YOY 0% -21% +2% +5% +17% Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 *No debt Gross Margin % GAAP Operating Margin % 82.3% 30.8% 80.9% 78.2% 81.5% 80.9% 29.2% 28.1
Slide 3: U.S. Utilization Mix, Q4 FY 2021
3 U.S. UTILIZATION MIX, Q4 FY 2021 Revenue by Impella® Device Utilization by Indication Impella 5.0® / 5.5 (15%) Other Impella RP® Emergent (4%) (4%) (56%) Impella 2.5® (4%) Protected PCI ® Impella CP ® (40%) (77%) Patient Performance Revenue Performance U.S. Hospital Site Penetration Sequential YOY
Slide 4: Updated Protected PCI Current Addressable Market With PROTECT IV
4 UPDATED PROTECTED PCI CURRENT ADDRESSABLE MARKET WITH PROTECT IV ON-LABEL ENROLLMENT FOR CLASS 1 GUIDELINES PROTECTED CARDIOGENIC RESPIRATORY HEART HEART ATTACK PCI SHOCK FAILURE (ECMO) FAILURE (STEMI) ✓ ✓ ✓ ✓ FDA STUDY ONGOING TAM = 440K 202K >25K ~100K ~200K (121K1-7 + 319K7) U.S. PATIENTS8 U.S.
Slide 5: A Growing Population Appropriate for PCI
5 A GROWING POPULATION APPROPRIATE FOR PCI 1.7M Patients Class III/IV Heart Failure1 Plus 261,000 Annual Incidence1 68% Have Coronary Artery Disease2 60% With Reduced Ejection Fraction3 55% 440,000 Good vessel targets and not CABG candidates4,5 28% (121,000)* 72% (319,000) Undiagnosed, Protected PCI
Slide 6: PROTECT Study Enrollment
6 PROTECT STUDY ENROLLMENT Only FDA RCT Ever Conducted for Hemodynamically Supported High-Risk PCI PROTECT III Patients Enrolled (N=1,611) ® ® Impella 2.5 IABP Impella CP 1143 791 448 223 352 20 225 PROTECT I PROTECT II PROTECT III FDA Pilot FDA Pivotal RCT FDA Prospective Study 2006-2007 2007-2010
Slide 7: Published Investigator-Led Studies for AMI Cardiogenic Shock
7 PUBLISHED INVESTIGATOR-LED STUDIES FOR AMI CARDIOGENIC SHOCK Demonstrating Improved Survival with Best Practices 82% 77% % Survival 71% 52% 52% 50% 49% 17% N=87 N=83 N=302 N=48 N=685 N=82 N=406 N=202 1973 1988 1999 2017 2017 2018-2019 2016-2021 2018-2021 Scheidt 1 Lee 2 Hochman 3 Ouweneel 4 Thiele
Slide 8: Impella Clinical Evidence Pathway
8 IMPELLA CLINICAL EVIDENCE PATHWAY 510(K) TO FDA APPROVALS TO CLASS I RECOMMENDATION GOALS Established Safety & Effectiveness Identify & Validate Best Practices Class I Guidelines Goal Pilot Studies, RCTs, RWE Physician Studies, RWE, Registries, FDA PAS Best Practice Impella Outcomes vs. Other Care
Slide 9: Appendix
APPENDIX FOR INVESTORS ONLY Recovering Hearts. Saving Lives.
Slide 10: Undertreatment of High-Risk Patients With Complex CAD
10 UNDERTREATMENT OF HIGH-RISK PATIENTS WITH COMPLEX CAD Contemporary PCI, CABG and Mechanical Circulatory Support (MCS) in 2019 984,000 PCI (In-Patient & Out-Patient, Excludes Diagnostic only)1 68,900 108,000 118,100 137,800 AKI2 Incomplete Patients Patients Revasc3-6 Readmitted7,8 Staged10 Surgica
Slide 11: Reassignment Proposed to Define Two Clinical Populations
11 REASSIGNMENT PROPOSED TO DEFINE TWO CLINICAL POPULATIONS: INTEROPERATIVE & NON-INTRAOPERATIVE PROCEDURES LOWER ACUITY/MODERATE RESOURCES HIGHER ACUITY/ HIGHER RESOURCES HIGHEST ACUITY/ HIGHEST RESOURCES CATH PROCEDURES INTRAOPERATIVE NON-INTRAOPERATIVE • Single vessel disease DEVICE REMOVED AT EN
Slide 12: Impella & Ecpella: Improving Outcomes & Lowering Costs
12 IMPELLA & ECPELLA: IMPROVING OUTCOMES & LOWERING COSTS Quality of Life Outcomes & Survival Cost-Effective Improvement in High-Risk PCI Improvement in Cardiogenic Shock Therapy 22 to Improvement of LVEF 77 to Improved Survival 2 to Hospital Stay Reduction 45% at 90-day follow up 1,2,3 82% with bes